DK3313436T3 - Multivalent pneumokok-konjugatvaccine - Google Patents
Multivalent pneumokok-konjugatvaccine Download PDFInfo
- Publication number
- DK3313436T3 DK3313436T3 DK16753710.9T DK16753710T DK3313436T3 DK 3313436 T3 DK3313436 T3 DK 3313436T3 DK 16753710 T DK16753710 T DK 16753710T DK 3313436 T3 DK3313436 T3 DK 3313436T3
- Authority
- DK
- Denmark
- Prior art keywords
- pneumokok
- multivalent
- conjugate vaccine
- vaccine
- conjugate
- Prior art date
Links
- 108010060123 Conjugate Vaccines Proteins 0.000 title 1
- 229940031670 conjugate vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3140CH2015 | 2015-06-23 | ||
| PCT/IN2016/000157 WO2016207905A2 (en) | 2015-06-23 | 2016-06-21 | Multivalent pneumococcal conjugate vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3313436T3 true DK3313436T3 (da) | 2021-03-08 |
Family
ID=56738144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16753710.9T DK3313436T3 (da) | 2015-06-23 | 2016-06-21 | Multivalent pneumokok-konjugatvaccine |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11147863B2 (da) |
| EP (1) | EP3313436B1 (da) |
| JP (1) | JP6808658B2 (da) |
| CN (1) | CN107810010A (da) |
| AU (1) | AU2016285017B2 (da) |
| BR (1) | BR112017028130A2 (da) |
| CA (1) | CA2989230A1 (da) |
| CY (1) | CY1123838T1 (da) |
| DK (1) | DK3313436T3 (da) |
| EA (1) | EA037373B1 (da) |
| ES (1) | ES2857474T3 (da) |
| HR (1) | HRP20210373T1 (da) |
| HU (1) | HUE053272T2 (da) |
| LT (1) | LT3313436T (da) |
| MX (1) | MX389480B (da) |
| PL (1) | PL3313436T3 (da) |
| PT (1) | PT3313436T (da) |
| RS (1) | RS61440B1 (da) |
| SA (1) | SA517390539B1 (da) |
| SI (1) | SI3313436T1 (da) |
| SM (1) | SMT202100121T1 (da) |
| WO (1) | WO2016207905A2 (da) |
| ZA (1) | ZA201708713B (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11160855B2 (en) * | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| JP6994453B2 (ja) * | 2015-07-21 | 2022-01-14 | ファイザー・インク | コンジュゲート化莢膜糖類抗原を含む免疫原性組成物、それを含むキットおよびこれらの使用 |
| WO2017173415A2 (en) * | 2016-03-31 | 2017-10-05 | Liffey Biotech Limited | Saccharide-polypeptide conjugate compositions and methods of use thereof |
| AU2017336806B2 (en) | 2016-09-30 | 2024-06-27 | Biological E Limited | Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates |
| AU2017388891C1 (en) | 2016-12-30 | 2025-04-17 | Vaxcyte, Inc. | Polypeptide-antigen conjugates with non-natural amino acids |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| BR112019026192B1 (pt) * | 2017-06-10 | 2022-05-10 | Inventprise, Llc | Vacinas de conjugado multivalente com polissacarídeos de conjugado bivalente ou multivalente que fornecem imunogenicidade e avidez melhoradas |
| US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
| US12257295B2 (en) | 2017-10-04 | 2025-03-25 | Pogona, LLC | Saccharide-polypeptide conjugate compositions and methods of use thereof |
| CN108003240B (zh) * | 2017-12-04 | 2020-06-05 | 西安德轩驰生物科技有限公司 | 一种海水养殖鱼多联抗独特型卵黄抗体疫苗及其制备方法 |
| AR114154A1 (es) | 2017-12-06 | 2020-07-29 | Merck Sharp & Dohme | Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y métodos de uso de estos |
| KR102486891B1 (ko) | 2018-02-05 | 2023-01-10 | 사노피 파스퇴르 인코포레이티드 | 다가 폐렴구균성 다당류-단백질 접합체 조성물 |
| AU2019256218A1 (en) | 2018-04-18 | 2020-12-03 | Sk Bioscience Co., Ltd. | Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof |
| CN113194987B (zh) * | 2018-10-12 | 2024-11-08 | 生物E有限公司 | 多价肺炎球菌多糖-蛋白缀合的疫苗 |
| KR20240169145A (ko) | 2018-12-19 | 2024-12-02 | 머크 샤프 앤드 돔 엘엘씨 | 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법 |
| EP3900739A1 (en) * | 2020-04-21 | 2021-10-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5360897A (en) | 1981-08-31 | 1994-11-01 | The University Of Rochester | Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad |
| EP1958646A1 (en) | 1992-02-11 | 2008-08-20 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Dual carrier immunogenic construct |
| PT616034E (pt) | 1993-03-05 | 2005-02-28 | Wyeth Corp | Plasmideo para a producao de proteina crm e toxina da difteria |
| AU678613B2 (en) | 1993-09-22 | 1997-06-05 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs |
| ATE241384T1 (de) | 1995-03-22 | 2003-06-15 | Jackson H M Found Military Med | Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden |
| FR2763244B1 (fr) | 1997-05-14 | 2003-08-01 | Pasteur Merieux Serums Vacc | Composition vaccinale multivalente a porteur mixte |
| US8048432B2 (en) | 2003-08-06 | 2011-11-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Polysaccharide-protein conjugate vaccines |
| US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| KR102611449B1 (ko) | 2005-04-08 | 2023-12-06 | 와이어쓰 엘엘씨 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| SI1962899T1 (sl) * | 2005-12-22 | 2011-11-30 | Glaxosmithkline Biolog Sa | Pnevmokokna polisaharidna konjugatna vakcina |
| KR101838938B1 (ko) | 2006-03-17 | 2018-03-15 | 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 | 복합 다가 면역원성 콘쥬게이트의 제조 방법 |
| ES2626662T3 (es) | 2007-06-26 | 2017-07-25 | Glaxosmithkline Biologicals S.A. | Vacuna que comprende conjugados de polisacárido capsular de Streptococcus pneumoniae |
| CN101590224A (zh) * | 2009-06-30 | 2009-12-02 | 广州精达医学科技有限公司 | 高效14价肺炎球菌结合疫苗 |
| TW201136603A (en) * | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
| GB201003924D0 (en) * | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| KR102057217B1 (ko) * | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| CN103623401A (zh) | 2012-08-23 | 2014-03-12 | 北京科兴中维生物技术有限公司 | 多价肺炎球菌荚膜多糖-蛋白质共轭组合物及其制备方法 |
| CN103656631B (zh) | 2012-09-24 | 2015-08-19 | 北京科兴中维生物技术有限公司 | 多价肺炎球菌荚膜多糖-蛋白缀合物组合物及其制备方法 |
| CN103656632B (zh) | 2012-09-24 | 2016-01-13 | 北京科兴中维生物技术有限公司 | 多价肺炎球菌荚膜多糖组合物、其制备方法及应用 |
| KR20140075196A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| KR20140075201A (ko) * | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| CN104069488A (zh) | 2013-03-29 | 2014-10-01 | 北京科兴中维生物技术有限公司 | 多价肺炎球菌荚膜多糖-蛋白质共轭组合物及其制备方法 |
| MX388191B (es) | 2014-11-20 | 2025-03-19 | Biological E Ltd | Polinucleótido optimizado por codones para la expresión de alto nivel de crm197. |
-
2016
- 2016-06-21 RS RS20210164A patent/RS61440B1/sr unknown
- 2016-06-21 SM SM20210121T patent/SMT202100121T1/it unknown
- 2016-06-21 PL PL16753710T patent/PL3313436T3/pl unknown
- 2016-06-21 ES ES16753710T patent/ES2857474T3/es active Active
- 2016-06-21 HR HRP20210373TT patent/HRP20210373T1/hr unknown
- 2016-06-21 EA EA201890431A patent/EA037373B1/ru unknown
- 2016-06-21 CA CA2989230A patent/CA2989230A1/en active Pending
- 2016-06-21 PT PT167537109T patent/PT3313436T/pt unknown
- 2016-06-21 MX MX2017016828A patent/MX389480B/es unknown
- 2016-06-21 BR BR112017028130A patent/BR112017028130A2/pt active Search and Examination
- 2016-06-21 LT LTEP16753710.9T patent/LT3313436T/lt unknown
- 2016-06-21 DK DK16753710.9T patent/DK3313436T3/da active
- 2016-06-21 WO PCT/IN2016/000157 patent/WO2016207905A2/en active Application Filing
- 2016-06-21 JP JP2017566871A patent/JP6808658B2/ja active Active
- 2016-06-21 EP EP16753710.9A patent/EP3313436B1/en active Active
- 2016-06-21 CN CN201680037079.2A patent/CN107810010A/zh active Pending
- 2016-06-21 SI SI201631120T patent/SI3313436T1/sl unknown
- 2016-06-21 US US15/772,771 patent/US11147863B2/en active Active
- 2016-06-21 HU HUE16753710A patent/HUE053272T2/hu unknown
- 2016-06-21 AU AU2016285017A patent/AU2016285017B2/en active Active
-
2017
- 2017-12-13 SA SA517390539A patent/SA517390539B1/ar unknown
- 2017-12-20 ZA ZA2017/08713A patent/ZA201708713B/en unknown
-
2021
- 2021-02-18 CY CY20211100136T patent/CY1123838T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE053272T2 (hu) | 2021-06-28 |
| ZA201708713B (en) | 2019-08-28 |
| BR112017028130A2 (pt) | 2018-08-28 |
| WO2016207905A2 (en) | 2016-12-29 |
| CN107810010A (zh) | 2018-03-16 |
| CY1123838T1 (el) | 2022-05-27 |
| MX2017016828A (es) | 2018-09-18 |
| SA517390539B1 (ar) | 2021-05-24 |
| LT3313436T (lt) | 2021-06-10 |
| US11147863B2 (en) | 2021-10-19 |
| WO2016207905A3 (en) | 2017-02-09 |
| ES2857474T3 (es) | 2021-09-29 |
| JP2018518512A (ja) | 2018-07-12 |
| SI3313436T1 (sl) | 2021-09-30 |
| HRP20210373T1 (hr) | 2021-04-30 |
| JP6808658B2 (ja) | 2021-01-06 |
| EA201890431A1 (ru) | 2018-06-29 |
| SMT202100121T1 (it) | 2021-05-07 |
| MX389480B (es) | 2025-03-20 |
| AU2016285017A1 (en) | 2018-01-04 |
| EA037373B1 (ru) | 2021-03-22 |
| EP3313436A2 (en) | 2018-05-02 |
| CA2989230A1 (en) | 2016-12-29 |
| US20190240308A1 (en) | 2019-08-08 |
| AU2016285017B2 (en) | 2022-03-03 |
| RS61440B1 (sr) | 2021-03-31 |
| PT3313436T (pt) | 2021-02-25 |
| PL3313436T3 (pl) | 2021-06-14 |
| EP3313436B1 (en) | 2020-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3313436T3 (da) | Multivalent pneumokok-konjugatvaccine | |
| DK3393510T3 (da) | Zikavirusvaccine | |
| MA46766A (fr) | Vaccin antigrippal | |
| EP3585803A4 (en) | PNEUMOCOCCIC CONJUGATE VACCINE FORMULATIONS | |
| DK3466976T3 (da) | Anti-her2-antistof-lægemiddelkonjugat | |
| EP3700565A4 (en) | VACCINES WITH ADJUVANT | |
| IL249643A0 (en) | Ophthalmic composition | |
| EP3364949A4 (en) | CANCER VACCINES | |
| DK3129063T3 (da) | Anti-her3-antistof-lægemiddelkonjugat | |
| EP3313857A4 (en) | POLYMER-CYCLODEXTRIN LIPID CONJUGATES | |
| DK3268047T3 (da) | Amatoxin/antistof-konjugater | |
| DK3119885T3 (da) | Antistof-fynomer-konjugater | |
| HUE040440T2 (hu) | Terápiás HPV16-oltóanyagok | |
| DK3148591T3 (da) | Nanopartikel-lægemiddelkonjugater | |
| EP3560512A4 (en) | COMPOSITION OF VACCINE AGAINST ZONA | |
| DK3129007T3 (da) | Vaccinesammensætninger | |
| ZA201800928B (en) | Multivalent vlp conjugates | |
| EP3511016A4 (en) | Immunostimulant | |
| IL264605A (en) | A multivalent vaccine | |
| EP3528843A4 (en) | Anti-opioid vaccines | |
| EP3562498A4 (en) | INFLUENZA VACCINES | |
| EP3500280A4 (en) | VIRUS VACCINES | |
| HUE047581T2 (hu) | Készítmény | |
| LT3188755T (lt) | Vakcina | |
| EP3706787A4 (en) | VACCINE |